Clinical Artificial Intelligence in Oncology: Opportunities, Challenges, and Future Directions

Abstract

Artificial intelligence (AI) is rapidly transforming clinical oncology by enabling data-driven approaches to cancer diagnosis, prognosis, treatment planning, therapeutic monitoring, and long-term survivorship care. The growing availability of electronic health records, medical imaging, digital pathology, genomic sequencing, molecular diagnostics, and real-world clinical data has created unprecedented opportunities for AI-driven precision medicine. Machine learning, deep learning, natural language processing, computer vision, multimodal learning, graph neural networks, and foundation models now support clinicians in interpreting complex biomedical information that exceeds conventional analytical capabilities. AI-assisted systems have demonstrated remarkable performance in tumor detection, disease classification, prognostic prediction, radiogenomics, computational pathology, treatment optimization, immunotherapy response prediction, adaptive radiation planning, and clinical decision support. In addition, emerging technologies such as generative AI, federated learning, explainable AI, and digital health platforms are expanding the role of intelligent clinical systems throughout the oncology care continuum. Despite these advances, widespread clinical implementation remains limited by challenges involving data quality, interoperability, algorithmic bias, transparency, cybersecurity, ethical governance, regulatory approval, clinician acceptance, and healthcare equity. This review discusses the current landscape of clinical artificial intelligence in oncology, highlighting major opportunities, existing limitations, technological innovations, and future directions that will shape the next generation of precision cancer care.[1]